DNA analysis at p53 locus in carcinomas arising from pleomorphic adenomas of salivary glands: Comparison of molecular study and p53 immunostaining

Pathology International

Volumn 48, Issue 4, 1998, Pages 265-272

  Yamamoto, Yuzo ^a,b,c   Kishimoto, Yosuke ^b   Wistuba, Ignacio I ^a,b   Virmani, Arvind K ^b   Vuitch, Frank ^a   Gazdar, Adi F ^b   Albores Saavedra, Jorge ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Immunohistochemistry; Loss of heterozygosity; P53 gene; Pleomorphic adenoma; Salivary gland carcinoma

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ALLELE; ARTICLE; CONTROLLED STUDY; DINUCLEOTIDE REPEAT; DNA DETERMINATION; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; PLEOMORPHIC ADENOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SALIVARY GLAND TUMOR;

EID: 0031818208     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.1998.tb03904.x     Document Type: Article

References (38)

1. Eneroth CM. Histological and clinical aspects of parotid tumors. Acta Otolaryngol. Suppl. (Stockh.) 1964; 191: 15-41.
2. Eneroth CM, Blanck C, Jakobsson PA. Carcinoma in pleomorphic adenoma of the parotid gland. Acta Otolaryngol. 1968; 66: 477-492.
3. Seifert G, Donath K. Die Morphologie der Speicheldrüsenerkrankungena. Arch. Oto-Rhino-Laryngol. 1976; 213: 111-208.
4. Tomich CE. Adenoid cystic carcinoma. In: Ellis GL, Auclair PL, Gnepp DR, eds. Surgical Pathology of the Salivary Glands. WB Saunders, Philadelphia, 1991; 333-349.
5. Sundaresan V, Ganly P, Hasleton R et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in pre-invasive lesions of the bronchus. Oncogene 1992; 7: 1989-1997.
6. Hung J, Kishimoto Y, Sugio K et al. Allele-specific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 1995; 273: 558-563.
7. Wistuba II, Sugio K, Hung J et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995; 55: 2511-2515.
8. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989; 342: 705-708.
9. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
10. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855-4878.
11. Deguchi H, Hamano H, Hayashi Y. c-myc, ras p21 and p53 expression in adenoma and its malignant form of the human salivary glands. Acta Pathol. Jpn. 1993; 43: 413-422.
12. Righi PD, Li Y, Deutsch M et al. The role of the p53 gene in the malignant transformation of pleomorphic adenomas of the parotid gland. Anticancer Res. 1994; 14: 2253-2258.
13. Gallo O, Franchi A, Bianchi S, Boddi V, Giannelli E, Alajmo E. p53 oncoprotein expression in parotid gland carcinoma is associated with clinical outcome. Cancer 1995; 75: 2037-2044.
14. Yamamoto Y, Kishimoto Y, Virmani AK et al. Mutations associated with carcinomas arising from pleomorphic adenomas of the salivary glands. Hum. Pathol. 1996; 27: 782-786.
15. Parada LF, Land H, Weinberg RA, Wolf D, Rotter V. Cooperation between gene encoding p53 tumor antigen and ras in cellular transformation. Nature 1984; 312: 649-651.
16. Sugio K, Kishimoto Y, Virmani A, Hung JY, Gazdar AF. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 1994; 54: 5811-5815.
17. Jones MH, Nakamura Y. Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat. Genes Chromosomes Cancer 1992; 5: 89-90.
18. Futreal PA, Barrett JC, Wiseman RW. An Alu polymorphism intragenic to the TP53 gene. Nucleic Acids Res. 1991; 19: 6977.
19. Kishimoto Y, Sugio K, Mitsudomi T et al. Frequent loss of the short arm of the chromosome 9 in resected non-small cell lung cancer from Japanese patients and its association with squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 1995; 121: 291-296.
20. Battifora H. p53 immunohistochemistry: A word of caution (editorial). Hum. Pathol. 1994; 25: 435-437.
21. Ellis GL, Auclair PL. Tumors of the Salivary Glands. Atlas of Tumor Pathology, Fascicle 17, Series 3. Armed Forces Institute of Pathology, Washington DC, 1995.
22. Seifert G. World Health Organization International Classification of Tumors. Histological Typing of Salivary Gland Tumors, 2nd edn. Springer-Verlag, Berlin, 1991.
23. Knudson AG. Hereditary cancers: Clues to mechanisms of carcinogenesis. Br. J. Cancer 1989; 59: 661-666.
24. Oren M. The p53 cellular tumor antigen: Gene structure, expression and protein properties. Biochem. Biophys. Acta 1985; 823: 67-68.
25. Levine AJ. Tumor suppressor genes. Bioessays 1990; 12: 60-66.
26. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant form of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-679.
27. Milner J, Cook A, Mason J. p53 is associated with p34cdc-2 in transformed cells. EMBO J. 1990; 9: 2885-2889.
28. Levine AJ, Momand L, Finlay CA. The p53 tumor suppressor gene. Nature 1991; 351: 453-456.
29. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935.
30. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948.
31. Soini Y, Kamel D, Nuorva K, Lane DP, Vahakangas K, Paakko P. Low p53 protein expression in salivary gland tumors compared with lung carcinomas. Virchows Arch. A Pathol. Anat. Histopathol. 1992; 421: 415-420.
32. Azuma M, Kasai Y, Tamatani T, Sato M. Involvement of p53 mutation in the development of human salivary gland pleomorphic adenomas. Cancer Lett. 1992; 65: 61-71.
33. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal tumor development. N. Engl. J. Med. 1988; 319: 525-532.
34. Baker SJ, Preisinger AC, Jessup JM et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 1990; 50: 7717-7722.
35. Kikuchi-Yanoshita R, Konishi M, Ito S et al. Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients. Cancer Res. 1992; 52: 3965-3971.
36. Gazdar AF, Bader S, Hung J et al. Molecular genetic changes found in human lung cancer and its precursor lesions. In: Cold Spring Harbor Symposia on Quantitative Biology, Volume LIX. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1994; 565-572.
37. Levine AJ. The tumor suppressor genes. Annu. Rev. Biochem. 1993; 62: 623-651.
38. Bodner SM, Minna JD, Jensen SM et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7: 743-749.